Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
April 15, 2019 16:02 ET | Autolus Therapeutics plc
LONDON, April 15, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Pricing of Public Offering
April 10, 2019 21:19 ET | Autolus Therapeutics plc
LONDON, April 10, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
April 08, 2019 16:40 ET | Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Host R&D Day on March 26, 2019
March 07, 2019 16:05 ET | Autolus Therapeutics plc
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...
Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
March 04, 2019 16:05 ET | Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
March 04, 2019 06:30 ET | Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...